Victrex Q3 Trading Update: Momentum Continues with 18% Revenue Growth and Maintained Guidance

Victrex Q3 trading update: 18% revenue growth shows recovery is real, but not risk-free

Victrex has delivered a solid third quarter, with revenue up 18% to £84.5 million and sales volumes up 17% to 1,238 tonnes. That is a strong improvement on last year and, importantly, management says the momentum seen in Q2 has carried on into Q3.

The headline message is pretty simple: demand has improved in parts of the business, cost savings are starting to come through, and full-year guidance has been kept unchanged. For retail investors, that usually reads as reassuring rather than exciting – but in Victrex’s case, steady progress matters because this business has been working through a softer patch.

Victrex Q3 2026 key numbers: revenue, volumes, pricing and guidance

Metric	Q3 2026	Q3 2025	Change
Revenue	£84.5 million	£71.5 million	+18%
Sales volume	1,238 tonnes	1,057 tonnes	+17%
Average selling price	£68/kg	£68/kg	Flat

Metric	YTD 2026	YTD 2025	Change
Revenue	£231.6 million	£217.3 million	+7%
Sales volume	3,375 tonnes	3,075 tonnes	+10%

The board also maintained full-year guidance for underlying PBT of £42 million to £44 million. PBT means profit before tax, and when a company repeats guidance rather than cutting it, that is normally a good sign.

What drove Victrex’s Q3 growth: Aerospace and Electronics did the heavy lifting

The strongest drivers in the quarter were Aerospace and Electronics within the Sustainable Solutions division. That tells you the recovery is not broad-based across everything, but it is coming through clearly in some attractive end markets.

There is an important caveat, though. Victrex says Aerospace had a much weaker prior year comparator because of industry supply chain backlogs in 2025. In plain English, part of this year’s growth looks strong because last year was unusually weak.

That does not make the growth fake, but it does mean investors should avoid getting carried away with the 18% revenue jump. Some of that is genuine momentum, and some of it is the benefit of easier comparisons.

Medical has stabilised, but it is not yet a big growth story

The company said Q3 performance was supported by “some stabilisation” in Medical. That wording matters. Stabilisation is better than deterioration, but it is not the same as saying Medical is growing strongly.

So the positive read is that a previously softer area may have stopped getting worse. The less positive read is that Victrex is still leaning more heavily on Aerospace and Electronics for the current rebound.

Victrex pricing and volumes: flat ASP means demand recovery is doing the work

Average selling price, or ASP, was £68/kg, unchanged from Q3 2025. That means the revenue growth in the quarter was mainly driven by higher volumes rather than higher pricing.

That is a decent outcome. In cyclical industrial businesses, volume growth is often the first sign that customers are ordering again. Flat pricing is not a problem in itself, but it does suggest Victrex is not currently getting an extra lift from price increases.

Year to date, volumes are up 10% while revenue is up 7%. The company has not disclosed the detailed reason for that gap, so it is best not to over-interpret it. Still, the Q3 data shows a healthier relationship between revenue and volume than the year-to-date picture.

Profit Improvement Plan: cost savings are coming, but there is a price to pay first

Victrex says it has made good progress simplifying the business, refreshing the leadership team and decentralising the organisation. Those are management phrases investors hear a lot, but the part that matters financially is much clearer: a headcount reduction of around 10% of roles.

Most employees directly affected had already left during Q3, and the company expects initial benefits in Q4. Victrex remains on track for annualised cost savings of at least £10 million, with those savings fully realised in FY 2027.

That is a positive for future margins, but it is not free money. The company has already flagged cash exceptional items of around £10 million for FY 2026. Exceptional items are one-off costs outside normal trading, often linked to restructuring.

My take is that this plan looks credible enough on paper. If Victrex can protect growth while taking out at least £10 million of annual costs, that should help profitability materially. But investors will want proof in the numbers, not just a slide deck at the Capital Markets Event.

Victrex balance sheet and dividend: net debt is manageable, but worth watching

Net debt at 30 June 2026 was £43.0 million, with cash of £27.5 million. That was after paying the interim dividend of 13.42p per share, which totalled about £12 million.

There is nothing in this update that suggests balance sheet stress. Still, Victrex is not sitting on a huge pile of net cash either, so continued delivery on profit and cash generation matters if it wants to keep funding dividends, investment and restructuring without pressure.

The RNS does not disclose borrowings in detail, financing costs or covenant information, so investors cannot go much further than that based on this statement alone.

Full-year guidance maintained: good news, but management is still cautious on demand and energy costs

Keeping guidance unchanged is one of the most important parts of this update. The board still expects FY 2026 underlying PBT of £42 million to £44 million, despite calling out normal seasonality, wider macroeconomic conditions, potential implications for global demand and energy costs.

That caution feels sensible rather than alarming. Management is essentially saying Q3 was good, but it is not declaring victory yet.

I think that is the right tone. The quarter was clearly better, but Victrex operates in end markets that can move around with industrial demand, and management is being honest that the final quarter still has variables attached.

What this Victrex RNS means for retail investors

• The good news: revenue and volumes both rose strongly in Q3, guidance was maintained, and cost savings are starting to appear.
• The nuance: Aerospace growth benefited from a weak prior-year comparator, so not all of the improvement should be treated as clean underlying growth.
• The watchpoint: Medical is only described as stabilising, not accelerating, and pricing was flat.
• The medium-term angle: if the Profit Improvement Plan lands properly, at least £10 million of annualised savings could make a meaningful difference to profits by FY 2027.

Overall, I would call this a positive update. Not a knockout, not a game-changer, but definitely a step in the right direction. Victrex is showing better demand, stable pricing in the quarter, and enough confidence to hold full-year expectations.

The next thing investors should look for is whether Q4 converts this improved trading into stronger profitability and cash flow. If it does, the recovery story starts to look more durable. If it does not, this quarter may end up looking more like a bounce than a breakout.

Bottom line on Victrex’s Q3 trading update

Victrex has put together a better quarter, with 18% revenue growth, 17% volume growth and no downgrade to full-year profit guidance. That is the kind of update shareholders needed to see.

The shares will likely still depend on whether management can turn this improving demand picture into sustained earnings progress. For now, the message is encouraging: momentum is back, but the hard work of proving it can last is still ahead.